The effect of abatacept on T-cell activation is not long-lived in vivo.
Discov Immunol
; 3(1): kyad029, 2024.
Article
en En
| MEDLINE
| ID: mdl-38567291
ABSTRACT
Abatacept, a co-stimulatory blocker comprising the extracellular portion of human CTLA-4 linked to the Fc region of IgG1, is approved for the treatment of rheumatoid arthritis. By impairing the interaction between CD28 on T cells and CD80/CD86 on APCs, its mechanisms of action include the suppression of follicular T helper cells (preventing the breach of self-tolerance in B cells), inhibition of cell cycle progression holding T cells in a state described as 'induced naïve' and reduction in DC conditioning. However, less is known about how long these inhibitory effects might last, which is a critical question for therapeutic use in patients. Herein, employing a murine model of OVA-induced DTH, we demonstrate that the effect of abatacept is short-lived in vivo and that the inhibitory effects diminish markedly when treatment is ceased.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Discov Immunol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Reino Unido